2026 Interim Report
Filed with HKEX · Stock code 2137 · · 73 pages · English
Brii Biosciences Limited on 6ix
Earlier from Brii Biosciences
- Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
- Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
- Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Later from Brii Biosciences
- Notification Letter and Change Request Form for Registered Shareholders
- Notification Letter and Request Form for Non-registered Shareholders
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Grant of share options and restricted share units
- Next Day Disclosure Return
Follow Brii Biosciences into a list and get an email when it puts out news.
Follow Brii Biosciences